S&P 500   3,577.59 (+0.56%)
DOW   29,591.27 (+1.12%)
QQQ   290.40 (+0.01%)
AAPL   114.08 (-2.78%)
MSFT   210.13 (-0.12%)
FB   268.85 (-0.32%)
GOOGL   1,727.00 (-0.54%)
AMZN   3,098.00 (-0.05%)
TSLA   522.72 (+6.76%)
NVDA   525.31 (+0.34%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.08 (+3.28%)
MU   64.18 (+4.53%)
AMD   85.25 (+0.72%)
T   28.60 (+0.99%)
NIO   55.61 (+12.91%)
F   8.85 (+1.26%)
ACB   7.18 (+0.70%)
GILD   59.88 (-0.38%)
NFLX   478.00 (-2.10%)
BA   211.67 (+6.04%)
DIS   145.94 (+3.45%)
S&P 500   3,577.59 (+0.56%)
DOW   29,591.27 (+1.12%)
QQQ   290.40 (+0.01%)
AAPL   114.08 (-2.78%)
MSFT   210.13 (-0.12%)
FB   268.85 (-0.32%)
GOOGL   1,727.00 (-0.54%)
AMZN   3,098.00 (-0.05%)
TSLA   522.72 (+6.76%)
NVDA   525.31 (+0.34%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.08 (+3.28%)
MU   64.18 (+4.53%)
AMD   85.25 (+0.72%)
T   28.60 (+0.99%)
NIO   55.61 (+12.91%)
F   8.85 (+1.26%)
ACB   7.18 (+0.70%)
GILD   59.88 (-0.38%)
NFLX   478.00 (-2.10%)
BA   211.67 (+6.04%)
DIS   145.94 (+3.45%)
S&P 500   3,577.59 (+0.56%)
DOW   29,591.27 (+1.12%)
QQQ   290.40 (+0.01%)
AAPL   114.08 (-2.78%)
MSFT   210.13 (-0.12%)
FB   268.85 (-0.32%)
GOOGL   1,727.00 (-0.54%)
AMZN   3,098.00 (-0.05%)
TSLA   522.72 (+6.76%)
NVDA   525.31 (+0.34%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.08 (+3.28%)
MU   64.18 (+4.53%)
AMD   85.25 (+0.72%)
T   28.60 (+0.99%)
NIO   55.61 (+12.91%)
F   8.85 (+1.26%)
ACB   7.18 (+0.70%)
GILD   59.88 (-0.38%)
NFLX   478.00 (-2.10%)
BA   211.67 (+6.04%)
DIS   145.94 (+3.45%)
S&P 500   3,577.59 (+0.56%)
DOW   29,591.27 (+1.12%)
QQQ   290.40 (+0.01%)
AAPL   114.08 (-2.78%)
MSFT   210.13 (-0.12%)
FB   268.85 (-0.32%)
GOOGL   1,727.00 (-0.54%)
AMZN   3,098.00 (-0.05%)
TSLA   522.72 (+6.76%)
NVDA   525.31 (+0.34%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.08 (+3.28%)
MU   64.18 (+4.53%)
AMD   85.25 (+0.72%)
T   28.60 (+0.99%)
NIO   55.61 (+12.91%)
F   8.85 (+1.26%)
ACB   7.18 (+0.70%)
GILD   59.88 (-0.38%)
NFLX   478.00 (-2.10%)
BA   211.67 (+6.04%)
DIS   145.94 (+3.45%)
Log in
NYSE:DVA

DaVita Stock Forecast, Price & News

$110.13
+0.28 (+0.25 %)
(As of 11/23/2020 03:59 PM ET)
Add
Compare
Today's Range
$109.01
Now: $110.13
$110.60
50-Day Range
$82.82
MA: $93.72
$113.39
52-Week Range
$62.20
Now: $110.13
$114.13
Volume26,120 shs
Average Volume1.24 million shs
Market Capitalization$12.33 billion
P/E Ratio16.51
Dividend YieldN/A
Beta1.18
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2019, it provided dialysis and administrative services in the United States through a network of 2,753 outpatient dialysis centers serving approximately 206,900 patients; and operated 259 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 28,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.
Read More
DaVita logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.8 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.78 out of 5 stars


Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryHealth Care Services
SectorMedical
CUSIP23918K10
Phone720-631-2100
Employees65,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.39 billion
Cash Flow$10.98 per share
Book Value$15.65 per share

Profitability

Net Income$810.98 million

Miscellaneous

Market Cap$12.33 billion
Next Earnings Date2/8/2021 (Estimated)
OptionableOptionable
$110.13
+0.28 (+0.25 %)
(As of 11/23/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











DaVita (NYSE:DVA) Frequently Asked Questions

How has DaVita's stock been impacted by Coronavirus?

DaVita's stock was trading at $74.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, DVA stock has increased by 47.2% and is now trading at $110.24.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of DaVita?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DaVita in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for DaVita
.

What stocks does MarketBeat like better than DaVita?

Wall Street analysts have given DaVita a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DaVita wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is DaVita's next earnings date?

DaVita is scheduled to release its next quarterly earnings announcement on Monday, February 8th 2021.
View our earnings forecast for DaVita
.

How were DaVita's earnings last quarter?

DaVita Inc. (NYSE:DVA) issued its quarterly earnings data on Thursday, October, 29th. The company reported $1.80 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.44 by $0.36. The business earned $2.92 billion during the quarter, compared to analysts' expectations of $2.94 billion. DaVita had a net margin of 7.32% and a return on equity of 43.99%. DaVita's quarterly revenue was up .7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.53 EPS.
View DaVita's earnings history
.

What guidance has DaVita issued on next quarter's earnings?

DaVita issued an update on its fourth quarter earnings guidance on Thursday, October, 29th. The company provided earnings per share (EPS) guidance of $1.77-2.02 for the period, compared to the Thomson Reuters consensus estimate of $1.67. The company issued revenue guidance of $2.85-2.96 billion, compared to the consensus revenue estimate of $2.94 billion.

What price target have analysts set for DVA?

6 brokerages have issued 1 year price targets for DaVita's shares. Their forecasts range from $60.00 to $100.00. On average, they anticipate DaVita's share price to reach $77.50 in the next twelve months. This suggests that the stock has a possible downside of 29.7%.
View analysts' price targets for DaVita
.

Are investors shorting DaVita?

DaVita saw a increase in short interest in October. As of October 15th, there was short interest totaling 5,610,000 shares, an increase of 16.1% from the September 30th total of 4,830,000 shares. Based on an average daily trading volume, of 1,090,000 shares, the days-to-cover ratio is currently 5.1 days. Currently, 4.7% of the company's shares are sold short.
View DaVita's Short Interest
.

Who are some of DaVita's key competitors?

What other stocks do shareholders of DaVita own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DaVita investors own include CA (CA), BlackRock (BLK), Chipotle Mexican Grill (CMG), Endologix (ELGX), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), AT&T (T), AbbVie (ABBV), Intel (INTC) and AutoZone (AZO).

Who are DaVita's key executives?

DaVita's management team includes the following people:
  • Mr. Javier J. Rodriguez, CEO & Exec. Director (Age 49, Pay $8.1M)
  • Mr. Joel Ackerman, CFO & Treasurer (Age 55, Pay $1.98M)
  • Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 52, Pay $2.44M)
  • Mr. Michael David Staffieri, Chief Operating Officer of Kidney Care (Age 46, Pay $6.49M)
  • Ms. LeAnne M. Zumwalt, Group VP of Purchasing & Public Affairs (Age 61, Pay $2.26M)
  • Mr. John D. Winstel, Chief Accounting Officer
  • Mr. Jim Gustafson, VP of Investor Relations
  • Mr. James O. Hearty, Chief Compliance Officer (Age 51)
  • Mr. Bill Myers, VP of Marketing & Communications
  • Mr. Kenny Gardner, Chief People Officer

What is DaVita's stock symbol?

DaVita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."

Who are DaVita's major shareholders?

DaVita's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.69%), State Street Corp (3.53%), LSV Asset Management (2.00%), Robeco Institutional Asset Management B.V. (1.42%), Charles Schwab Investment Management Inc. (0.55%) and UBS Asset Management Americas Inc. (0.53%). Company insiders that own DaVita stock include Barbara J Desoer, Charles Berg, John M Nehra, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway, Paul J Diaz and R Ted Weschler.
View institutional ownership trends for DaVita
.

Which institutional investors are selling DaVita stock?

DVA stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, BlackRock Inc., State Street Corp, Mackay Shields LLC, Wedge Capital Management L L P NC, Achmea Investment Management B.V., Los Angeles Capital Management & Equity Research Inc., and Great West Life Assurance Co. Can. Company insiders that have sold DaVita company stock in the last year include Barbara J Desoer, Charles Berg, John M Nehra, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway, Paul J Diaz, and R Ted Weschler.
View insider buying and selling activity for DaVita
.

Which institutional investors are buying DaVita stock?

DVA stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management, Jupiter Asset Management Ltd., Iron Triangle Partners LP, AJO LP, First Trust Advisors LP, Point72 Asset Management L.P., Todd Asset Management LLC, and Sei Investments Co..
View insider buying and selling activity for DaVita
.

How do I buy shares of DaVita?

Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DaVita's stock price today?

One share of DVA stock can currently be purchased for approximately $110.24.

How big of a company is DaVita?

DaVita has a market capitalization of $12.35 billion and generates $11.39 billion in revenue each year. The company earns $810.98 million in net income (profit) each year or $5.40 on an earnings per share basis. DaVita employs 65,000 workers across the globe.

What is DaVita's official website?

The official website for DaVita is www.davita.com.

How can I contact DaVita?

DaVita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 720-631-2100 or via email at [email protected]

This page was last updated on 11/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.